{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:18:17Z","timestamp":1784744297464,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Perampanel (PER) is an oral antiepileptic drug and its concomitant use with carbamazepine (CBZ) leads to decreased PER concentrations. However, the magnitude of its influence may vary, depending on the dynamics of the enzyme induction properties of CBZ. This study aimed to develop a population pharmacokinetic (PPK) model considering the dynamics of enzyme induction and evaluate the effect of CBZ on PER pharmacokinetics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively collected data on patient background, laboratory tests, and prescribed drugs from electronic medical records. We developed 2 PPK models incorporating the effect of CBZ-mediated enzyme induction to describe time\u2013concentration profiles of PER using the following different approaches: (1) treating the concomitant use of CBZ as a categorical covariate (empirical PPK model) and (2) incorporating the time-course of changes in the amount of enzyme by CBZ-mediated induction (semimechanistic PPK model). The bias and precision of the predictions were investigated by calculating the mean error, mean absolute error, and root mean squared error.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 133 PER concentrations from 64 patients were available for PPK modelling. PPK analyses showed that the co-administration of CBZ increased the clearance of PER. Goodness-of-fit plots indicated a favorable description of the observed data and low bias. The mean error, mean absolute error, and root mean square error values based on the semimechanistic model were smaller than those obtained using the empirical PPK model for predicting PER concentrations in patients with CBZ.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We developed 2 PPK models to describe PER pharmacokinetics based on different approaches, using electronic medical record data. Our PPK models support the use of PER in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001055","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T17:00:22Z","timestamp":1673888422000},"page":"653-659","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetic Analysis of Drug\u2013Drug Interactions Between Perampanel and Carbamazepine Using Enzyme Induction Model in Epileptic Patients"],"prefix":"10.1097","volume":"45","author":[{"given":"Yuito","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Science, Kyushu University, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Science, Kyushu University, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Muraki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Science, Kyushu University, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Suetsugu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Science, Kyushu University, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2019.02.022","article-title":"Plasma concentration and clinical effects of perampanel\u2014the Kork experience","volume":"67","author":"Steinhoff","year":"2019","journal-title":"Seizure"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yebeh.2019.02.004","article-title":"Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy","volume":"94","author":"Ishikawa","year":"2019","journal-title":"Epilepsy Behav."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.seizure.2020.10.017","article-title":"Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy","volume":"83","author":"Yamamoto","year":"2020","journal-title":"Seizure"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des Develop Ther."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/fcp.12081","article-title":"The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy","volume":"28","author":"El Desoky","year":"2014","journal-title":"Fundam Clin Pharmacol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eplepsyres.2016.08.025","article-title":"Pharmacokinetics, exposure\u2013cognition, and exposure\u2013efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures","volume":"127","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","year":"2018","journal-title":"Acta Neurol Scand."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers","volume":"320","author":"Faucette","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/bcp.14503","article-title":"Drug\u2013drug and drug\u2013food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet","volume":"87","author":"Welzel","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab Dispos."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of com- puter intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Computer Methods Programs Biomed."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ane.13286","article-title":"Changes in perampanel levels during de-induction: simulations following carbamazepine discontinuation","volume":"142","author":"Schuck","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.clpt.6100431","article-title":"Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin","volume":"84","author":"Magnusson","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":"Population pharmacokinetics of carbamazepine in Chinese epilepsy patients","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jcpt.12152","article-title":"Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam","volume":"39","author":"Zhou","year":"2014","journal-title":"J Clin Pharm Ther."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St Louis","year":"2009","journal-title":"Curr Neuropharmacol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1684\/j.1950-6945.2003.tb00001.x","article-title":"Rational conversion from antiepileptic polytherapy to monotherapy","volume":"5","author":"Baulac","year":"2003","journal-title":"Epileptic Disord."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:08Z","timestamp":1748970848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001055","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-05-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}